Inovio Cost Of Revenue vs Minority Interest Analysis
INO Stock | USD 11.50 0.93 8.80% |
Inovio Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Inovio Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Inovio Pharmaceuticals is a good investment. Please check the relationship between Inovio Pharmaceuticals Cost Of Revenue and its Minority Interest accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inovio Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.
Cost Of Revenue vs Minority Interest
Cost Of Revenue vs Minority Interest Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Inovio Pharmaceuticals Cost Of Revenue account and Minority Interest. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Inovio Pharmaceuticals' Cost Of Revenue and Minority Interest is -0.38. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Minority Interest in the same time period over historical financial statements of Inovio Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Inovio Pharmaceuticals' Cost Of Revenue and Minority Interest is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Inovio Pharmaceuticals are associated (or correlated) with its Minority Interest. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Minority Interest has no effect on the direction of Cost Of Revenue i.e., Inovio Pharmaceuticals' Cost Of Revenue and Minority Interest go up and down completely randomly.
Correlation Coefficient | -0.38 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Cost Of Revenue
Cost of Revenue is found on Inovio Pharmaceuticals income statement and represents the costs associated with goods and services Inovio Pharmaceuticals provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Minority Interest
Minority Interest is the portion of a subsidiary corporation stock that is not owned by the parent corporation. The magnitude of the minority interest in the subsidiary company is generally less than 50% of outstanding shares, otherwise the corporation would generally cease to be a subsidiary of the parent. Minority Interest can also be called non-controlling interest.All shareholders of Inovio Pharmaceuticals whose combined shares represent less than 50% of the total outstanding shares issued by Inovio Pharmaceuticals have a minority interest in Inovio Pharmaceuticals.Most indicators from Inovio Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Inovio Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inovio Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.At this time, Inovio Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 30th of April 2024, Sales General And Administrative To Revenue is likely to grow to 60.05, while Issuance Of Capital Stock is likely to drop about 9.8 M.
2021 | 2022 | 2023 | 2024 (projected) | Total Revenue | 1.8M | 10.3M | 832.0K | 790.4K | Interest Expense | 1.9M | 1.3M | 1.2M | 1.2M |
Inovio Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Inovio Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Inovio Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 144.0M | 539.8M | 495.9M | 348.5M | 172.9M | 131.2M | |
Total Current Liabilities | 32.0M | 41.7M | 65.7M | 96.9M | 42.6M | 23.4M | |
Total Stockholder Equity | 3.4M | 461.1M | 399.7M | 222.4M | 117.3M | 95.2M | |
Property Plant And Equipment Net | 26.6M | 24.1M | 29.0M | 18.0M | 14.5M | 7.5M | |
Net Debt | 77.3M | (211.7M) | (38.1M) | (14.3M) | 15.9M | 16.7M | |
Retained Earnings | (739.8M) | (906.2M) | (1.2B) | (1.5B) | (1.6B) | (1.5B) | |
Accounts Payable | 7.6M | 1.5M | 24.8M | 80.9M | 4.6M | 7.3M | |
Cash | 22.2M | 250.7M | 71.1M | 46.3M | 14.3M | 13.6M | |
Non Current Assets Total | 49.8M | 68.6M | 47.5M | 33.3M | 19.8M | 28.2M | |
Cash And Short Term Investments | 89.5M | 411.6M | 401.3M | 253.0M | 145.3M | 92.0M | |
Net Receivables | 2.0M | 19.1M | 8.0M | 11.7M | 2.4M | 3.9M | |
Common Stock Shares Outstanding | 8.2M | 12.9M | 17.4M | 19.9M | 22.2M | 28.0M | |
Liabilities And Stockholders Equity | 144.0M | 539.8M | 495.9M | 348.5M | 172.9M | 131.2M | |
Non Current Liabilities Total | 106.6M | 36.9M | 30.5M | 29.3M | 13.0M | 12.1M | |
Other Current Assets | 2.6M | 40.5M | 39.1M | 50.5M | 5.4M | 6.9M | |
Other Stockholder Equity | 742.6M | 1.4B | 1.6B | 1.7B | 1.7B | 1.8B | |
Total Liab | 138.5M | 78.6M | 96.3M | 126.2M | 55.6M | 35.5M | |
Property Plant And Equipment Gross | 26.6M | 24.1M | 48.0M | 18.0M | 35.3M | 37.1M | |
Total Current Assets | 94.2M | 471.2M | 448.4M | 315.2M | 153.1M | 103.0M | |
Accumulated Other Comprehensive Income | 472.6K | (256.2K) | (282.2K) | (698.7K) | (662.6K) | (629.5K) | |
Intangible Assets | 3.7M | 3.1M | 2.6M | 2.1M | 2.4M | 2.3M | |
Other Current Liab | 22.1M | 37.9M | 38.4M | 13.2M | 18.7M | 19.7M | |
Other Liab | 9.1M | 206.4K | 111.2K | 32.0K | 36.9K | 35.0K | |
Non Currrent Assets Other | (5.4M) | 22.2M | (1.5M) | (1.6M) | 605.3K | 635.6K | |
Other Assets | 2.7M | 43.6M | 1.4M | 684.0K | 1.0 | 0.95 | |
Common Stock Total Equity | 101.4K | 186.9K | 217.4K | 253.1K | 227.8K | 216.4K | |
Common Stock | 101.4K | 186.9K | 217.4K | 253.1K | 22.8K | 21.7K | |
Property Plant Equipment | 12.8M | 11.3M | 17.5M | 7.7M | 8.9M | 5.2M | |
Current Deferred Revenue | 257.2K | 124.1K | 46.6K | 21.6K | 24.9K | 23.6K | |
Short Term Investments | 67.3M | 160.9M | 330.2M | 206.7M | 131.0M | 85.0M | |
Net Tangible Assets | (10.8M) | 447.5M | 386.5M | 209.7M | 241.2M | 159.6M | |
Retained Earnings Total Equity | (739.8M) | (906.2M) | (1.2B) | (1.5B) | (1.3B) | (1.3B) | |
Capital Surpluse | 742.6M | 1.4B | 1.6B | 1.7B | 2.0B | 2.1B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inovio Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Complementary Tools for Inovio Stock analysis
When running Inovio Pharmaceuticals' price analysis, check to measure Inovio Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inovio Pharmaceuticals is operating at the current time. Most of Inovio Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Inovio Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inovio Pharmaceuticals' price. Additionally, you may evaluate how the addition of Inovio Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |
Is Inovio Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inovio Pharmaceuticals. If investors know Inovio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inovio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.09) | Revenue Per Share 0.038 | Quarterly Revenue Growth (0.18) | Return On Assets (0.32) | Return On Equity (0.80) |
The market value of Inovio Pharmaceuticals is measured differently than its book value, which is the value of Inovio that is recorded on the company's balance sheet. Investors also form their own opinion of Inovio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Inovio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Inovio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inovio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.